Literature DB >> 21304540

Prostate cancer in 2010: GSU: misclassification or biological progression?

Umberto Capitanio1, Nazareno Suardi.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21304540     DOI： 10.1038/nrurol.2010.247

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

Authors:  Felix K-H Chun; Thomas Steuber; Andreas Erbersdobler; Eike Currlin; Jochen Walz; Thorsten Schlomm; Alexander Haese; Hans Heinzer; Michael McCormack; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2005-12-22       Impact factor: 20.096

2.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.

Authors:  Roderick C N van den Bergh; Stijn Roemeling; Monique J Roobol; Gunnar Aus; Jonas Hugosson; Antti S Rannikko; Teuvo L Tammela; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

3.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

4.  Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range.

Authors:  D Colleselli; A E Pelzer; E Steiner; S Ongarello; G Schaefer; G Bartsch; C Schwentner
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-12-22       Impact factor: 5.554

5.  Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.

Authors:  Marc A Dall'Era; Janet E Cowan; Jeffrey Simko; Katsuto Shinohara; Benjamin Davies; Badrinath R Konety; Maxwell V Meng; Nannette Perez; Kirsten Greene; Peter R Carroll
Journal:  BJU Int       Date:  2011-04       Impact factor: 5.588

6.  Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Authors:  Derya Tilki; Boris Schlenker; Majnu John; Alexander Buchner; Peter Stanislaus; Christian Gratzke; Alexander Karl; Gerald Y Tan; Süleyman Ergün; Ashutosh K Tewari; Christian G Stief; Michael Seitz; Oliver Reich
Journal:  Urol Oncol       Date:  2009-10-17       Impact factor: 3.498

7.  Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Authors:  Girish S Kulkarni; Gina Lockwood; Andrew Evans; Ants Toi; John Trachtenberg; Michael A S Jewett; Antonio Finelli; Neil E Fleshner
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

8.  Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.

Authors:  Nazareno Suardi; Umberto Capitanio; Felix K H Chun; Markus Graefen; Paul Perrotte; Thorsten Schlomm; Alexander Haese; Hartwig Huland; Andreas Erbersdobler; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.

Authors:  Ayman S Moussa; Michael W Kattan; Ryan Berglund; Changhong Yu; Khaled Fareed; J Stephen Jones
Journal:  BJU Int       Date:  2009-08-13       Impact factor: 5.588

10.  Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Authors:  Umberto Capitanio; Pierre I Karakiewicz; Luc Valiquette; Paul Perrotte; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi
Journal:  Urology       Date:  2009-02-04       Impact factor: 2.649
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.